School of Medicine
Showing 11-20 of 63 Results
-
Max Kasun
Bio Max Kasun works in the Roberts Ethics Lab at Stanford.
-
Makoto Kawai
Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Stanford Center for Sleep Sciences and Medicine
Bio I am a physician scientist in the field of sleep medicine in aging and brain function. Using combined polysomnogram and novel neuroimaging technology, I aim to identify potential sleep biomarkers to investigate the mechanism of progression from normal aging to Mild Cognitive Impairment (MCI) or dementia. I also investigate the impact of sleep on cognitive/affective function or behavior abnormality in various neurodevelopmental and neurodegenerative disorders.
-
Debra Lee Kaysen
Professor of Psychiatry and Behavioral Sciences (Public Mental Health & Population Sciences) at the Stanford University Medical Center
Bio Debra Kaysen received her PhD in Clinical Psychology from the University of Missouri. She completed an internship at the University of Washington and continued there to complete an NIAAA-funded F32 to study the area of overlap between PTSD and alcohol use disorders. Dr. Kaysen joined the faculty at University of Washington in 2006 in the Department of Psychiatry and Behavioral Sciences. While there she founded a program to develop and test more accessible interventions for individuals suffering from mental health symptoms following traumatic events. Dr. Kaysen joined the Stanford faculty in 2019.
Dr. Kaysen’s area of specialty both in research and clinical work is in treatment of those who have experienced traumatic events including PTSD, mood and substance use disorders. She has conducted critical studies on bidirectional relationships between PTSD and alcohol use, and on the treatment of PTSD and/or substance use across a variety of populations (sexual minority women, Native Americans, young adult sexual assault survivors, active duty military) and in a variety of settings (the Democratic Republic of Congo, Iraq, primary care, rural settings). Dr. Kaysen has been on the Board of Directors for the International Society for Traumatic Stress Studies (ISTSS) since 2013 and is currently the ISTSS President-Elect. Her research has been funded by the National Institute of Alcohol Abuse and Alcoholism, the National Institute of Drug Abuse, the National Institute on Minority Health and Health Disparities, the Department of Defense, and USAID. -
Corey Keller, MD, PhD
Instructor, Psychiatry and Behavioral Sciences
Current Research and Scholarly Interests The overarching goal of my research is to identify and apply individualized stimulation protocols to elicit precise and predictable long-term plasticity in order to alleviate psychiatric suffering. Repetitive transcranial magnetic stimulation (TMS) was FDA approved for treatment-resistant depression over 10 years ago as a circuit-based, targeted intervention that complements traditional psychiatric treatments. Remission rates, however, remain at 15% at worst and 40% at best. TMS trials using identical treatment settings are currently underway for bipolar disorder, PTSD, OCD, and addiction. The low efficacy and one-size-fits-all treatment (with respect to timing, site, and intensity) stems from our lack of understanding of how TMS induces brain changes. It is reasonable to expect that we can improve the efficacy of TMS. By selecting the optimal parameters based on the stimulation timing, location, intensity, and duration of the TMS pulses, we can customize treatment to maximize an individual’s clinical response. My 10 year research aims are to obtain this level of specificity and treatment response by:
1) Developing an integrated translational clinical research program.
2) Identifying the specific neural mechanisms underlying repetitive stimulation-induced plasticity.
3) Creating novel treatments with TMS based on experimentally-driven computational models of plasticity.
This three-pronged approach has the expected outcome of producing novel stimulation treatments with enhanced specificity, plasticity, and efficacy. By increasing our understanding of the underlying mechanism and monitoring of brain changes during TMS, we will markedly increase the utility of these powerful techniques. Together, this work will help transform interventional psychiatry from an isolated (from a clinic perspective), one-size-fits-all treatment approach to one that focuses on targeting objective biomarkers and that is collaborative, large-scale, and automated, pushing the field into the age of personalized neuromodulation.
